Alternative treatments covered by insurance should be discussed to ensure financial considerations do not unduly influence treatment decisions when more established alternatives exist
DFG TI239/16-1 (PI Timmann)) Ethics declarations Conflicts of Interest LN Miterko, J Beckinghausen, RV Sillitoe: None LV Bradnam, AB McCambridge: None J Cooperrider, KB Baker, A Machado: None M Hallett: Member of the scientific advisory board of Brainsway T Popa: None DH Heck: None T Wichmann, MR DeLong: None SV Gornati, FE Hoebeek: None AZ Kouzani: None S-H Kuo, T Xie, ED Louis: None M Manto, N Oulad Ben Taib: None MA Nitsche: Member of the scientific advisory board of Neuroelectrics M Tanaka: None D Timmann: None MY Cheng, EH Wang, GK Steinberg: None Additional information Publishers Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
TB-500 : Promotes angiogenesis and reduces fibrotic tissue formation in injury models ( 7, 9 )
Un spectacle naturel permanent qui ravira petits et grands
And for tendon injuries specifically: tendons are slow to heal